Welcome to our dedicated page for enGene Holdings SEC filings (Ticker: ENGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for enGene Holdings Inc. (NASDAQ: ENGN), a British Columbia–incorporated, clinical-stage biotechnology company developing non-viral genetic medicines. Through these filings, investors can review how enGene reports clinical, regulatory, financial, and governance developments related to its lead program, detalimogene voraplasmid, and its broader corporate activities.
enGene’s current reports on Form 8-K provide detail on material events such as updated preliminary efficacy and safety data from the Phase 2 LEGEND trial in high-risk non-muscle invasive bladder cancer (NMIBC), changes to trial endpoints following discussions with the U.S. Food and Drug Administration, and enrollment status across LEGEND cohorts. Other 8-K filings describe executive and board appointments, amendments to executive employment agreements, and inducement equity awards granted under NASDAQ Listing Rule 5635(c)(4).
Filings also confirm that enGene’s common shares trade on The Nasdaq Stock Market LLC under the symbol ENGN, with warrants listed under ENGNW, and identify the company as an emerging growth company. Liquidity and capital structure information, including cash, cash equivalents and marketable securities balances and details of public offerings of common shares and pre-funded warrants, appear in financial disclosures and referenced exhibits.
On Stock Titan, users can access these SEC documents alongside AI-powered summaries that explain key points in clear language. Real-time updates from EDGAR surface new 8-Ks and other filings as they are submitted, while AI highlights sections related to clinical trial results, regulatory designations such as RMAT and Fast Track, manufacturing readiness programs like the FDA’s CDRP, and board or management changes. Form 4 insider transaction data, when filed, and periodic reports such as 10-K and 10-Q can be reviewed with AI-generated insights to help readers quickly understand complex regulatory and financial information.
enGene Holdings Inc. is registering an aggregate of
The prospectus lists the securities that may be offered from time to time — common shares, preferred shares, debt securities, subscription receipts, warrants and units — and states specific terms will be provided in prospectus supplements.
enGene Holdings Inc. filed Amendment No. 1 to its annual report to add the previously omitted Part III disclosures on directors, governance, executive compensation, ownership and auditor matters, and to update certain exhibits.
The amendment does not change prior financial statements and is meant to be read together with the original annual report. It details a nine‑member, majority‑independent, staggered board, outlines the roles of key committees, and describes the company’s code of conduct and insider trading policy. It also provides 2025 compensation data for the CEO, CFO and Chief Medical Officer and summarizes the 2023 Incentive Equity Plan, including stock option practices, severance terms and change‑of‑control treatment for equity awards.
enGene Holdings Inc. (ENGN) received an updated large-holder disclosure as Venrock-affiliated funds and related individuals reported beneficial ownership of 4,771,414 Common Shares, representing 7.1% of the company as of December 31, 2025.
The ownership is spread across Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., and related management entities, with Nimish Shah and Bong Y. Koh as voting members. The percentage is based on 66,984,661 Common Shares outstanding as of December 17, 2025. The group certifies the shares were not acquired to change or influence control of enGene.
Cormorant Asset Management, LP and Bihua Chen have disclosed a significant passive stake in enGene Holdings Inc. common shares. They report beneficial ownership of 4,000,000 common shares, representing 5.97% of the class, held through certain Cormorant funds.
The percentage is calculated using 66,984,661 common shares outstanding as of December 17, 2025, as stated in enGene’s Form 10-K. All 4,000,000 shares are reported with shared voting and shared dispositive power, with no sole voting or dispositive power. The holding is certified as being in the ordinary course of business and not for the purpose of changing or influencing control of enGene.
Kynam Capital Management and related reporting persons disclose a 2.23% beneficial stake in enGene Holdings Inc. common shares on an amended Schedule 13G. They report beneficial ownership of 1,492,898 common shares, with shared voting and dispositive power and no sole voting or dispositive authority.
The filing names Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang as reporting persons and certifies the shares are held in the ordinary course of business, not for the purpose of changing or influencing control of enGene.
enGene Holdings Inc. reported a new equity award to its Chief Scientific Officer, Anthony Tzeyew Cheung. On January 30, 2026, he received a stock option to buy 195,000 common shares at an exercise price of $9.53 per share.
The option vests monthly in substantially equal amounts over 48 months, conditioned on his continued service. After this grant, he beneficially owns 195,000 derivative securities directly, aligning his compensation more closely with the company’s future share performance.
enGene Holdings Inc. reported a new stock option grant to its Chief Legal Officer and Corporate Secretary, Lee G. Giguere. On 01/30/2026, Giguere received a stock option for 195,000 common shares with an exercise price of $9.53, reported as held directly.
The option was granted at no cost and is structured to vest monthly in substantially equal amounts over 48 months, subject to Giguere’s continued service with the company. After this grant, Giguere beneficially owned 195,000 stock options tied to enGene common shares.
enGene Holdings Inc. granted a stock option to Chief Strategy & Ops Officer Alexander Julian Nichols covering 195,000 common shares on January 30, 2026.
The option has an exercise price of $9.53 per share and expires on January 30, 2036. It was granted at no cost to the reporting person and vests in substantially equal monthly installments over 48 months, conditioned on continued service. After this grant, Nichols beneficially owns 195,000 derivative securities directly.
enGene Holdings Inc. reported that Chief Financial Officer D. Ryan Daws received a new stock option grant. On 01/30/2026, he was awarded a Stock Option (Right to Buy) covering 220,000 common shares at an exercise price of $9.53 per share, for no upfront cost.
The option expires on 01/30/2036 and is held directly. It vests monthly in substantially equal amounts over 48 months, conditioned on his continued service with the company, so the right to purchase shares builds gradually over four years rather than all at once.
enGene Holdings Inc. CEO & President Ronald Harold Wilfred Cooper was granted a large stock option award. On 01/30/2026, he received a stock option covering 801,000 common shares at an exercise price of $9.53 per share. The option was reported as held directly.
The option vests monthly in substantially equal amounts over 48 months, conditioned on his continued service. After this grant, he beneficially owned 801,000 derivative securities tied to common shares through this option award.